-
2025-520632-42-00
5
axial or predominantly axial SpA with or without psoriasis
-
2025-520842-31-00
5
Population of study participants Pregnant women with PPROM at 22 to 33
-
2025-520946-31-00
1
Non-Small Cell Lung Cancer
-
2025-520976-25-00
4
Relapsed/refractory multiple myeloma
-
2025-521037-86-00
5
Immune system diseases
-
2025-521038-27-00
5
Immune system diseases
-
2025-521173-13-00
1
Advanced Solid Tumors
-
2025-521317-50-00
5
Cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs)
-
2025-521322-14-00
4
Patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation,
-
2025-521331-36-00
10
Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%)
-
2025-521394-13-00
1
Relapsed/refractory Acute Myeloid Leukemia or relapsed/refractory myel
-
2025-521437-88-00
4
head and neck squamous cell carcinoma
-
2025-521478-32-00
5
PEDIATRIC ACUTE MYOCARDITIS
-
2025-521571-30-00
5
Young Adults and adults with R/R B-cell acute lymphoblastic leukemia (
-
2025-521982-29-00
4
Adult patients with advanced hormone receptor positive (HR+), HER2- br
-
2025-522060-32-00
4
STEMI (ST elevated Myocardial Infarction)
-
2025-522462-73-00
6
Postanesthetic complications in patients undergoing open hepatectomy
-
2025-522511-42-00
4
Crohn's disease
-
2025-522791-92-00
5
Neoplasm Metastasis
-
2025-522855-25-00
5
Carcinoma, Transitional Cell
-
2025-522904-26-00
3
Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephri
-
2025-522932-15-00
3
Systemic Lupus Erythematosus
-
2025-523094-42-00
5
Hirschsprung's disease
-
2025-523285-25-00
5
Relapsed or Refractory Multiple Myeloma